Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment

NAUnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions
Ebola Virus Disease
Interventions
PROCEDURE

Convalescent Plasma Treatment

This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).

Trial Locations (1)

Unknown

RECRUITING

ELWA-2 Ebola Treatment Unit, Monrovia

All Listed Sponsors
lead

Clinical Research Management, Inc.

INDUSTRY

NCT02333578 - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment | Biotech Hunter | Biotech Hunter